Unauthorised Use of Nine Sensor Samba Data in Commercial Marketing

Recently, we became aware that i-Sens has published a marketing infographic promoting the CareSens Air continuous glucose monitoring (CGM) system. The infographic references Diabettech and our Nine Sensor Samba evaluation, a single-participant comparison of nine CGM devices conducted in real-world daily use.

To be clear: Diabettech did not provide permission for our results, analysis, or commentary to be used in commercial marketing materials. No request was made, and no authorisation was granted.

The infographic presented selected data points from the evaluation, but it omitted relevant contextual results and allowed viewers to infer device rankings that do not reflect the complete findings. It also appeared to suggest endorsement or validation by Diabettech, which is incorrect. We do not endorse individual manufacturers and maintain independence across all testing published on this platform.

While we are flattered that i-Sens consider an n=1 experiment worthy of turning into a marketing infographic, and we encourage transparent discussion of CGM performance, medical device marketing must follow strict rules to avoid misleading consumers. Selective presentation of comparative accuracy data carries risk, especially when aimed at people making decisions about diabetes management.

We have therefore contacted i-Sens formally, requested the removal of the infographic from all marketing channels, and asked that no further use of Diabettech content occurs without prior written consent. We will monitor the situation and consider escalations if required.

For clarity:

The Nine Sensor Samba is not a clinical trial.

It is not intended to generate marketing-grade comparative claims.

It is designed to empower the diabetes community with open, real-world experience data.

We remain committed to independent evaluation, transparent methodology, and accuracy. We will continue to publish device performance insights, but we cannot allow commercial entities to extract, reframe, or selectively promote our work without approval.

Thank you to the diabetes community for your continued trust and engagement. If you see marketing material referencing Diabettech or our work, we welcome you flagging it to us at info@diabettech.com.

We will share any meaningful updates as they develop.